These findings hold immense promise for improving the treatment of advanced NS-NSCLC patients with PD-L1 expression ≥ 50%, and bring us one step closer to more effective, personalized therapies for lung cancer[38]. This evidence concerns the gene CD274 and lung carcinoma.